-
Company Insights
Innovation and Patenting activity of Idp Education Ltd Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Idp Education Ltd Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IDP-121 in Relapsed Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IDP-121 in Relapsed Multiple Myeloma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IDP-121 in Relapsed Multiple Myeloma Drug Details: IDP-121 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IDP-121 in Diffuse Large B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IDP-121 in Diffuse Large B-Cell Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IDP-121 in Diffuse Large B-Cell Lymphoma Drug Details: IDP-121...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IDP-121 in Relapsed Chronic Lymphocytic Leukemia (CLL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IDP-121 in Relapsed Chronic Lymphocytic Leukemia (CLL) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IDP-121 in Relapsed Chronic Lymphocytic Leukemia (CLL) Drug...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – (Benzoyl Peroxide + Tretinoin) in Acne Vulgaris
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Benzoyl Peroxide + Tretinoin) in Acne Vulgaris report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Benzoyl Peroxide + Tretinoin) in Acne Vulgaris Drug Details:...
-
Thematic Analysis
Edtech – Thematic Intelligence
Edtech Thematic Intelligence Report Overview Education technology (EdTech) gained prominence during the COVID-19 pandemic as travel restrictions forced schools and other educational institutions to teach online. The technologies that comprise edtech include artificial intelligence (AI), which aids in content creation, the customization of learning processes, evaluating performances, ensuring real-time communication, and automating grading. Additionally, VR and AR create appealing environments for students through virtual elements and situations. In an AR and VR classroom setup, both teachers and students perform tasks...
-
Product Insights
Refractory Chronic Lymphocytic Leukemia (CLL) – Drugs In Development, 2023
Global Markets Direct’s, ‘Refractory Chronic Lymphocytic Leukemia (CLL) - Drugs In Development, 2023’, provides an overview of the Refractory Chronic Lymphocytic Leukemia (CLL) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Refractory Chronic Lymphocytic Leukemia (CLL), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Relapsed Chronic Lymphocytic Leukemia (CLL) – Drugs In Development, 2023
Global Markets Direct’s, ‘Relapsed Chronic Lymphocytic Leukemia (CLL) - Drugs In Development, 2023’, provides an overview of the Relapsed Chronic Lymphocytic Leukemia (CLL) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Relapsed Chronic Lymphocytic Leukemia (CLL), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...